Exhaled Nitric Oxide Detectors

Exhaled Nitric Oxide Detectors Market Outlook

The global exhaled nitric oxide detectors market is poised for significant growth, projected to reach approximately USD 250 million by the year 2035, growing at a robust CAGR of 8.5% during the forecast period from 2025 to 2035. This upward trajectory is driven by increasing awareness regarding respiratory diseases, complementary advancements in diagnostic technologies, and the growing prevalence of asthma and chronic obstructive pulmonary disease (COPD), which necessitate effective monitoring solutions. The need for non-invasive, rapid diagnostic tools for assessing airway inflammation is also contributing to market growth, as healthcare providers seek better methods of patient management. Furthermore, with the rise of telemedicine and home healthcare solutions, the demand for portable and user-friendly devices has surged, positioning the market for substantial expansion.

Growth Factor of the Market

Several factors are driving the growth of the exhaled nitric oxide detectors market. First and foremost is the increasing incidence of asthma and allergies, which affects millions globally and requires proper management and monitoring. As more healthcare providers recognize the significance of measuring exhaled nitric oxide levels as a biomarker for airway inflammation, the demand for these devices is expected to rise. Additionally, advancements in technology have led to the development of highly sensitive and specific detectors that improve the accuracy of diagnostics, further increasing adoption rates among medical professionals. The growing emphasis on preventive healthcare and regular monitoring of chronic respiratory diseases also plays a crucial role in expanding the market landscape. Lastly, the rise of home healthcare settings and the convenience provided by portable and wearable devices are reshaping how patients manage their conditions, thus driving demand for exhaled nitric oxide detectors.

Key Highlights of the Market

• Projected market size of USD 250 million by 2035.
• Strong CAGR of 8.5% anticipated during the forecast period.
• Increasing prevalence of asthma and COPD driving market demand.
• Technological advancements enhancing device sensitivity and accuracy.
• Growth in home healthcare settings bolstering demand for portable devices.

By Product Type

Handheld Devices:

Handheld exhaled nitric oxide detectors are gaining traction due to their portability and ease of use. These devices allow for real-time monitoring of nitric oxide levels in a patient's breath, enabling quick diagnostics and assessments of airway inflammation. The compact size of handheld devices makes them ideal for use in outpatient settings, homecare, and emergency situations. As patients and healthcare providers continue to prioritize mobility and convenience, the demand for handheld devices is expected to increase significantly, contributing to the overall growth of the market.

Tabletop Devices:

Tabletop exhaled nitric oxide detectors are typically used in clinical and hospital settings for more comprehensive diagnostics. These devices offer enhanced accuracy and advanced features, making them suitable for detailed analysis and research purposes. Their larger size allows for more sophisticated technology, which can lead to better sensitivity and faster processing times. As healthcare facilities increasingly adopt sophisticated diagnostic tools to enhance patient care, the tabletop segment is expected to see consistent growth during the forecast period.

Wearable Devices:

Wearable exhaled nitric oxide detectors represent a significant innovation in respiratory health monitoring. By providing continuous monitoring capabilities, these devices enable patients to track their respiratory health in real-time without the need for frequent visits to a healthcare facility. This convenience not only empowers patients to take charge of their health but also helps healthcare providers in making timely interventions. With the growing trend toward personalized medicine and remote patient monitoring, the wearable devices segment is poised for substantial growth in the upcoming years.

Portable Devices:

Portable exhaled nitric oxide detectors combine the features of handheld and wearable devices, offering flexibility and ease of use. These devices are designed for individuals who require consistent monitoring of their respiratory condition while on the go. As the healthcare industry shifts towards home healthcare solutions and telemedicine, portable devices have become increasingly popular. Their compact and lightweight design allows users to carry them easily, making them a preferred choice for both patients and healthcare providers looking for convenient monitoring solutions.

Benchtop Devices:

Benchtop exhaled nitric oxide detectors are typically utilized in research laboratories and specialized diagnostic centers where in-depth analysis and research on respiratory diseases take place. These devices provide high accuracy and reliability, making them essential for clinical studies and advanced diagnostics. The benchtop segment is expected to maintain a steady growth trajectory as more research institutions and healthcare organizations invest in sophisticated laboratory equipment to improve patient outcomes and further understand respiratory-related conditions.

By Application

Asthma Diagnosis:

Asthma diagnosis remains one of the primary applications for exhaled nitric oxide detectors. Elevated levels of nitric oxide in exhaled breath are indicative of airway inflammation, a key feature in asthma. As doctors seek to establish more accurate diagnosis protocols, the incorporation of nitric oxide measurements into asthma assessments has become increasingly common. The growing prevalence of asthma globally, coupled with increasing patient awareness of the disease, drives the demand for effective diagnostic tools that can promptly identify asthma and facilitate appropriate treatment strategies.

Monitoring of Airway Inflammation:

Monitoring airway inflammation is critical for managing various respiratory diseases, including asthma and COPD. Exhaled nitric oxide detectors provide healthcare providers with valuable data to assess the effectiveness of treatment regimens. Regular monitoring enables timely adjustments to medications, leading to better patient outcomes. As the healthcare sector continues to emphasize preventive care and proactive disease management, the demand for devices facilitating airway inflammation monitoring is expected to increase significantly.

Chronic Obstructive Pulmonary Disease (COPD) Diagnosis:

COPD diagnosis benefits from the use of exhaled nitric oxide detectors, as elevated levels of nitric oxide can indicate exacerbations and inflammation associated with the disease. As the global burden of COPD continues to rise, driven by factors such as smoking and air pollution, the demand for reliable diagnostic tools is becoming increasingly apparent. Healthcare providers require accurate and efficient diagnostic methods to enhance the management of COPD, making the application of nitric oxide detectors integral to the overall care of patients suffering from this condition.

Cystic Fibrosis Diagnosis:

Cystic fibrosis is a genetic disorder that leads to severe respiratory complications, making early diagnosis crucial for improving patient quality of life. Exhaled nitric oxide detectors can assist in diagnosing cystic fibrosis by measuring the levels of inflammation in the lungs. With advancements in detection technology, these devices have become essential tools for healthcare providers in identifying cystic fibrosis in its early stages. As awareness of cystic fibrosis increases, the reliance on non-invasive diagnostic methods such as nitric oxide detection is anticipated to grow.

Others:

In addition to the primary applications mentioned above, exhaled nitric oxide detectors are also employed in various other conditions associated with respiratory inflammation. This includes their use in diagnosing and monitoring allergic reactions and other pulmonary disorders. The growing recognition of the importance of measuring exhaled nitric oxide levels has led to its adoption in a broader range of applications, driving further demand for these devices across the healthcare sector.

By Chronic Obstructive Pulmonary Disease

Mild COPD:

In patients with mild COPD, exhaled nitric oxide detectors serve an essential role in monitoring airway inflammation and guiding treatment decisions. Since mild COPD is often characterized by relatively stable symptoms, regular assessments of nitric oxide levels can help identify early signs of exacerbation, allowing for timely intervention. The increasing focus on preventing exacerbations and optimizing treatment plans is driving the demand for these devices in managing mild COPD effectively.

Moderate COPD:

For individuals with moderate COPD, continuous monitoring via exhaled nitric oxide detectors is critical in managing symptoms and reducing the frequency of exacerbations. Elevated levels of nitric oxide can indicate inflammation and worsening respiratory function, prompting healthcare providers to adjust treatment as needed. As the healthcare landscape shifts toward more personalized and proactive approaches, the demand for effective monitoring tools in moderate COPD management is expected to rise significantly.

Severe COPD:

Severe COPD patients often require more intensive monitoring and management strategies to maintain their quality of life. Exhaled nitric oxide detectors play a vital role in these strategies by providing data on airway inflammation and guiding therapeutic interventions. Given the complexity of severe COPD, healthcare providers are increasingly leveraging these devices to facilitate targeted treatments and improve patient outcomes. The rising prevalence of severe COPD is anticipated to bolster the demand for exhaled nitric oxide detectors within this segment.

By Distribution Channel

Hospitals & Clinics:

Hospitals and clinics remain the primary distribution channels for exhaled nitric oxide detectors due to the high volume of respiratory patients treated in these settings. The availability of advanced diagnostic tools is crucial for healthcare providers in delivering effective patient care. The integration of nitric oxide measurement into routine clinical practice is becoming standard, further solidifying hospitals and clinics as critical distribution points for these devices. As healthcare facilities continue to adopt innovative diagnostic technologies, the demand for these detectors is expected to grow significantly in this channel.

Homecare Settings:

The homecare segment is witnessing substantial growth as more patients prefer managing their respiratory conditions in the comfort of their homes. The convenience of portable exhaled nitric oxide detectors allows patients to monitor their condition regularly, thus reducing the need for frequent hospital visits. This trend aligns with the overall shift toward telemedicine and remote patient monitoring, making homecare settings a vital distribution channel for these devices. The increasing patient emphasis on self-management is expected to drive further demand for nitric oxide detectors in homecare environments.

Diagnostic Centers:

Diagnostic centers serve as specialized facilities for conducting detailed assessments and analyses of respiratory conditions. The utilization of exhaled nitric oxide detectors in these centers allows for accurate and efficient diagnostic capabilities. As expertise in respiratory health continues to evolve, diagnostic centers are increasingly adopting advanced diagnostic tools to enhance patient care. This trend is expected to bolster the demand for exhaled nitric oxide detectors in diagnostic centers, as their adoption leads to improved diagnostic accuracy and patient outcomes.

Online Retail:

The rise of e-commerce and online retail has transformed the distribution landscape for exhaled nitric oxide detectors, providing patients and healthcare providers with easy access to a range of diagnostic tools. The convenience of purchasing devices online has made it easier for patients to obtain necessary monitoring equipment without the need for in-person visits to pharmacies or medical supply stores. As consumer trends continue to favor online shopping, the online retail channel is anticipated to grow significantly, increasing overall market accessibility.

By Technology

Chemiluminescence Analyzer:

Chemiluminescence analyzers are sophisticated devices that utilize chemical reactions to measure nitric oxide levels in exhaled breath. Their high sensitivity and specificity make them a valuable tool for accurately assessing airway inflammation. As healthcare providers seek reliable diagnostic methods for respiratory diseases, the adoption of chemiluminescence analyzers is steadily increasing. This technology is particularly popular in clinical and research settings, where precision is paramount in patient management and treatment strategies.

Electrochemical Sensor:

Electrochemical sensors are widely used in exhaled nitric oxide detectors due to their cost-effectiveness and reliability. These sensors operate by measuring the current produced during the oxidation of nitric oxide, making them suitable for point-of-care testing and portable devices. The growing preference for accessible and efficient diagnostic solutions is driving the adoption of electrochemical sensors in various healthcare applications. Their integration into handheld and portable devices is expected to further enhance their market presence.

Laser-based Sensor:

Laser-based sensors utilize advanced optical techniques to measure nitric oxide levels with high accuracy and rapid response times. Their non-invasive nature and ability to provide real-time data make them highly valuable in both clinical and research settings. As the demand for precise diagnostic tools grows, the utilization of laser-based technology in exhaled nitric oxide detectors is expected to increase significantly. This technology is particularly appealing for applications requiring high sensitivity and specificity in measuring airway inflammation.

Photoacoustic Spectroscopy:

Photoacoustic spectroscopy is an innovative technology that detects nitric oxide through the absorption of laser light, which generates acoustic signals. This method offers high sensitivity and specificity, making it suitable for detecting low levels of nitric oxide in exhaled breath. The growing interest in non-invasive diagnostic techniques is propelling the adoption of photoacoustic spectroscopy in exhaled nitric oxide detectors. As research continues to advance in this field, the market for photoacoustic technology is expected to expand.

By Region

North America is currently the largest market for exhaled nitric oxide detectors, accounting for approximately 40% of the global market share in 2025. The region's dominance can be attributed to the high prevalence of respiratory diseases, advanced healthcare infrastructure, and increasing investments in respiratory diagnostics. Furthermore, the growing focus on preventive healthcare measures and the rising adoption of telemedicine are anticipated to drive significant growth in the North American market. The CAGR for this region is expected to be approximately 9.2% during the forecast period.

Europe follows closely behind, holding around 30% of the global market share in 2025. The presence of established healthcare systems, increasing awareness of respiratory health issues, and the rising demand for innovative diagnostic solutions are key factors contributing to the region's growth. Additionally, the European market is witnessing a rise in research activities focused on respiratory diseases, leading to enhanced product development and adoption. As a result, the European exhaled nitric oxide detectors market is projected to experience robust growth in the coming years.

Opportunities

The exhaled nitric oxide detectors market is poised for numerous opportunities as healthcare systems continue to evolve and prioritize patient-centric solutions. One significant opportunity lies in the expansion of telemedicine services, which encourages remote monitoring of chronic respiratory diseases. As more patients seek to manage their health from home, the demand for portable and user-friendly devices is expected to rise. Healthcare providers can leverage this trend to offer comprehensive care solutions that integrate nitric oxide monitoring, improving patient outcomes while reducing the burden on healthcare facilities. Additionally, ongoing advancements in technology, such as the development of more sensitive and specific detection methods, present an opportunity for companies to innovate and enhance their product offerings, further driving market growth.

Another opportunity exists within emerging markets, where the increasing prevalence of respiratory diseases presents a significant growth prospect for exhaled nitric oxide detector manufacturers. As healthcare access improves and awareness of respiratory health issues rises, the demand for diagnostic tools is expected to surge in these regions. Companies can target these markets by developing cost-effective and accessible solutions that cater to local healthcare needs. Collaborations with governments, NGOs, and healthcare organizations to promote awareness and early diagnosis of respiratory diseases can further facilitate market penetration in these regions, unlocking new revenue streams for manufacturers.

Threats

Despite the promising outlook for the exhaled nitric oxide detectors market, several threats pose challenges to its growth trajectory. One major threat is the presence of alternative diagnostic methods for assessing respiratory diseases, such as spirometry and imaging techniques. These established methods may overshadow the adoption of exhaled nitric oxide detectors, particularly in regions where healthcare providers are more accustomed to traditional diagnostics. Additionally, concerns regarding the accuracy and reliability of some exhaled nitric oxide measurement devices could hinder their acceptance among healthcare professionals. To counteract these threats, manufacturers must prioritize the development of highly accurate, reliable, and user-friendly devices that demonstrate clear advantages over existing diagnostic approaches.

Moreover, regulatory challenges can also act as a restraining factor for market growth. Navigating the complex landscape of medical device regulations and obtaining necessary approvals can be time-consuming and expensive for manufacturers. This may limit the entry of new players into the market and reduce competition, ultimately affecting device innovation and accessibility. Companies must remain vigilant and proactive in understanding regulatory requirements and ensuring compliance to mitigate these challenges and sustain growth in the exhaled nitric oxide detectors market.

Competitor Outlook

• Graham Medical
• Medtronic
• Alere (Abbott Laboratories)
• NIOX
• Aerocrine
• Health Care Logistics
• Quidel Corporation
• Respiratory Technology Inc.
• HITACHI Chemical Diagnostics
• CareFusion (BD)
• Vitalograph
• Vyaire Medical
• Sibel Medica
• Chembio Diagnostic Systems
• GSK

The competitive landscape of the exhaled nitric oxide detectors market is characterized by a mix of established players and emerging companies, each striving to innovate and capture market share. Leading companies are investing in research and development to enhance the accuracy, sensitivity, and speed of their devices, which is crucial for maintaining a competitive edge. As the market continues to evolve, key players are also focusing on strategic collaborations and partnerships to expand their product offerings and enhance distribution capabilities. In addition, companies are increasingly leveraging digital marketing and e-commerce platforms to reach a broader audience and facilitate sales, particularly in the growing homecare segment.

Graham Medical is one of the prominent players specializing in respiratory diagnostic solutions, known for its commitment to developing high-quality exhaled nitric oxide detectors. The company has established a strong presence in North America, leveraging its extensive distribution network to reach healthcare providers effectively. Similarly, Medtronic has expanded its portfolio to include innovative respiratory diagnostics, focusing on integrating exhaled nitric oxide measurement into its existing respiratory solutions. This approach not only enhances the company's reputation as a leader in respiratory care but also expands its market reach.

Another notable player is Alere (Abbott Laboratories), which has made significant strides in the market by offering a range of reliable and accurate exhaled nitric oxide detectors. The company's commitment to research and development has enabled it to remain competitive by continuously improving its product offerings. Likewise, NIOX and Aerocrine have established themselves as key players in the field, focusing on advanced technologies that provide high precision and reliability for nitric oxide measurement. As these companies continue to innovate and respond to market demands, they are likely to play a crucial role in shaping the future of the exhaled nitric oxide detectors market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GSK
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 NIOX
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Aerocrine
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Medtronic
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Vitalograph
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sibel Medica
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Graham Medical
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Vyaire Medical
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 CareFusion (BD)
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Quidel Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Health Care Logistics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Chembio Diagnostic Systems
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Alere (Abbott Laboratories)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Respiratory Technology Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 HITACHI Chemical Diagnostics
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Exhaled Nitric Oxide Detectors Market, By Technology
    • 6.1.1 Chemiluminescence Analyzer
    • 6.1.2 Electrochemical Sensor
    • 6.1.3 Laser-based Sensor
    • 6.1.4 Photoacoustic Spectroscopy
    • 6.1.5 Others
  • 6.2 Exhaled Nitric Oxide Detectors Market, By Application
    • 6.2.1 Asthma Diagnosis
    • 6.2.2 Monitoring of Airway Inflammation
    • 6.2.3 Chronic Obstructive Pulmonary Disease (COPD) Diagnosis
    • 6.2.4 Cystic Fibrosis Diagnosis
    • 6.2.5 Others
  • 6.3 Exhaled Nitric Oxide Detectors Market, By Product Type
    • 6.3.1 Handheld Devices
    • 6.3.2 Tabletop Devices
    • 6.3.3 Wearable Devices
    • 6.3.4 Portable Devices
    • 6.3.5 Benchtop Devices
  • 6.4 Exhaled Nitric Oxide Detectors Market, By Distribution Channel
    • 6.4.1 Hospitals & Clinics
    • 6.4.2 Homecare Settings
    • 6.4.3 Diagnostic Centers
    • 6.4.4 Online Retail

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Exhaled Nitric Oxide Detectors Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Exhaled Nitric Oxide Detectors market is categorized based on

By Product Type

• Handheld Devices
• Tabletop Devices
• Wearable Devices
• Portable Devices
• Benchtop Devices

By Application

• Asthma Diagnosis
• Monitoring of Airway Inflammation
• Chronic Obstructive Pulmonary Disease (COPD) Diagnosis
• Cystic Fibrosis Diagnosis
• Others

By Distribution Channel

• Hospitals & Clinics
• Homecare Settings
• Diagnostic Centers
• Online Retail

By Technology

• Chemiluminescence Analyzer
• Electrochemical Sensor
• Laser-based Sensor
• Photoacoustic Spectroscopy
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Graham Medical
• Medtronic
• Alere (Abbott Laboratories)
• NIOX
• Aerocrine
• Health Care Logistics
• Quidel Corporation
• Respiratory Technology Inc.
• HITACHI Chemical Diagnostics
• CareFusion (BD)
• Vitalograph
• Vyaire Medical
• Sibel Medica
• Chembio Diagnostic Systems
• GSK